Calcitriol or 1,25-dihydroxyvitamin D 3 [1, 25(OH) 2 D 3 ] has antitumor activity and hence its levels in patients may play an important role in disease outcome. Here, we report that the antineoplastic agents, daunorubicin hydrochloride, etoposide, and vincristine sulfate inhibited the ability of 1,25(OH) 2 D 3 to cause the accumulation of mRNA for kidney 25-hydroxyvitamin D 3 24-hydroxylase (CYP24), an enzyme which catabolizes this hormone. This was not due to a drug-induced cytotoxic effect, reduction in the expression of the vitamin D receptor or inhibition of the vitamin D receptor -mediated activation of the mitogen-activated protein kinases or CYP24 promoter activity. Interestingly, there was selective degradation of CYP24 mRNA in the presence of the drugs. This was accompanied by an enhancement in the levels of 1,25(OH) 2 D 3 in cells incubated with 25-hydroxy vitamin D 3 . These data identify a novel mechanism of action of some commonly used antineoplastic agents which by decreasing the stability of CYP24 mRNA would prolong the bioavailability of 1,25(OH) 2 D 3 for anticancer actions. [Mol Cancer Ther 2007;6(12):3131 -8] 
Introduction
Calcitriol or 1,25-dihydroxyvitamin D 3 [1, 25(OH) 2 D 3 ] and analogues have received much interest as anticancer agents because the secosteroid hormone has shown antitumor activity (1 -3) . Furthermore, 1,25(OH) 2 D 3 and analogues can enhance, either synergistically or additively, the antitumor activities of several classes of antineoplastic agents (3, 4) . These findings have led to clinical trials to evaluate the efficacy of combining 1,25(OH) 2 D 3 and drugs such as docetaxel (taxotere) in the treatment of androgen-independent prostate cancer (3, 5, 6) . How such combinations enhance the antitumor activity of each other is poorly understood.
The steady state level of circulating 1,25(OH) 2 D 3 is determined by a balance between 1,25(OH) 2 D 3 bioactivation and degradation (7) . Bioactivation of vitamin D involves firstly the 25-hydroxylation of inactive vitamin D 3 in the liver to form 25(OH)D 3 (7) . This is followed by 1a-hydroxylation catalyzed by the cytochrome P450 enzyme, 25-hydroxyvitamin D 3 1a-hydroxylase (CYP27B1), in the kidneys to produce the biologically active 1,25(OH) 2 D 3 in the circulation. Metabolic inactivation of 1,25(OH) 2 D 3 is catalyzed by the C23/C24-oxidation pathway (7) , where multiple steps are performed by another cytochrome P450 enzyme, 25-hydroxyvitamin D 3 , that is also expressed in the kidney. To prevent the excessive accumulation of 1,25(OH) 2 D 3 and its toxic hypercalcemic effects, CYP24 expression is up-regulated by 1,25(OH) 2 D 3 in a negative feedback mechanism (8) . CYP24 also catalyzes the removal of 25(OH)D 3 from the body (9) .
Previous studies have shown that mitogen-activated protein (MAP) kinases play important roles in mediating the stimulatory effect of 1,25(OH) 2 D 3 on CYP24 expression (10, 11) . Interestingly, antineoplastic agents are known to stimulate the activity of MAP kinases (12 -15) . Thus, a regulatory effect of antineoplastic agents on CYP24 expression seemed likely. Our data show that daunorubicin hydrochloride, etoposide, and vincristine sulfate, three well-characterized antineoplastic agents, caused the accumulation of 1,25(OH) 2 . The Dual Luciferase Assay System was from Promega. TRIzol and SuperScript III reverse transcriptase were purchased from Invitrogen. Random hexamer primers, deoxynucleotide triphosphates, and PCR primers were purchased from Geneworks. Primers designed to amplify cDNA for CYP24 (F, 5 ¶-cctgctgccagattctctggaa-3 ¶; R, 5 ¶-atacttcttgtggtactccacca-3 ¶), CYP27B1 (F, 5 ¶-tggcccagatcctaacacattt-3 ¶; R, 5 ¶-gtccgggtcttgggtctaact-3 ¶), VDR (F, 5 ¶-ggacgcccaccataagaccta-3 ¶; R, 5 ¶-ctccctccaccatcattcaca-3 ¶), and GAPDH (F, 5 ¶-acccagaagactgtggatgg-3 ¶; R, 5 ¶-cagtgagcttcccgttcag-3 ¶) were based on Genebank sequences (CYP24 accession no., NM000782; CYP27B1 accession no., NM000785; VDR accession no., X67482; GAPDH accession no., NM002046). The iQ SYBR Green Supermix was purchased from Bio-Rad Laboratories.
Plasmids The CYP24 promoter firefly luciferase constructs containing either proximal À298 or À1401 bp of the CYP24 promoter sequence together with 74 bp of the 5 ¶-untranslated region in pGL3 basic vector have been described previously (10) . The pRL-null vector containing the Renilla luciferase was purchased from Promega Corp.
Transfection and CYP24 Promoter Activity COS-1 African green monkey kidney interstitial fibroblast or human embryonic kidney (HEK293T) cells were seeded (40,000/well) in a 24-well tray and grown in DMEM containing 5% FCS and antibiotics (10, 11) . The cells were transfected as described previously (10, 11) . After an overnight culture, the medium was replaced with serumfree medium and the cells were treated with a drug in the presence or absence of 1,25(OH) 2 D 3 (10 nmol/L). Control cells received vehicle (<0.1% v/v). After 24 h, the cells were harvested and the lysates were assayed for dual luciferase activity using a TD20/20 Luminometer (Turner Design Instruments).
RNA Extraction and Real-time PCR Total RNA (1 Ag), extracted using TRIzol, was reversetranscribed using Random hexamers and SuperScript III reverse transcriptase. Real-time PCR reactions were carried out in duplicate in a final volume of 10 AL. The cDNA samples were amplified using iQ SYBR Green Supermix primers (250 nmol/L) as described above. Relative expression between samples was calculated using the comparative cycle threshold (C T ) method (DC T ; ref. 16) ERK1/ERK2 and ERK5 Activity Assays The activities of immunoprecipitated ERK1/ERK2 and ERK5 were assayed as described previously using myelin basic protein as a substrate (17, 18) .
Western Blots Western blotting was conducted as described previously (17) . Briefly, lysate proteins were separated by 12% SDS-PAGE, transferred to nitrocellulose membrane, and probed with anti-VDR antibody. The immune complexes were detected by enhanced chemiluminescence. The blots were stripped and reprobed with anti -h-actin antibody. The films were scanned using a Canon Canoscan 9900F scanner.
Statistical Analysis Statistical analysis was done using Student's unpaired t test or the Tukey-Kramer multiple comparisons test.
Results

Antineoplastic Agents Caused the Accumulation of 1,25(OH) 2 D 3
To gain an idea of whether antineoplastic agents could modulate the levels of 1,25(OH) 2 in vitro model for investigation. We selected daunorubicin hydrochloride and etoposide, two well-characterized topoisomerase II inhibitors, and the Vinca alkaloid, vincristine sulfate, to study. These agents were investigated at concentrations similar to those found in the plasma of patients (19, 20) . As shown in The above data could have been caused by an increased conversion of 25(OH)D 3 to 1,25(OH) 2 D 3 or an inability to degrade the 1,25(OH) 2 D 3 that was formed. We therefore investigated the expression of CYP27B1 and CYP24. The data in Table 1 and Fig. 2 suggest that inhibition of the negative feedback control was the more likely cause because the drugs inhibited the ability of 1,25(OH) 2 D 3 to up-regulate the level of CYP24 mRNA without affecting the level of CYP27B1 mRNA. Etoposide and daunorubicin hydrochloride were more effective than vincristine sulfate at inhibiting the 1,25(OH) 2 D 3 -mediated accumulation of CYP24 mRNA level ( Fig. 2A and B) . Similar inhibitory effects were observed at 4 or 6 h (data not shown). None of the drugs tested affected basal mRNA levels. These data suggest that antineoplastic agents could interrupt the negative feedback regulation of 1,25(OH) 2 D 3 by suppressing the ability of 1,25(OH) 2 D 3 to up-regulate the level of CYP24 mRNA.
Effects of Antineoplastic Agents on the Expression of VDR
To investigate how the drugs inhibited the up-regulation of CYP24 mRNA by 1,25(OH) 2 D 3 , we incubated COS-1 and HEK293T with daunorubicin hydrochloride or etoposide (Fig. 3A) and examined the expression of the VDR. The drugs caused a modest but clear increase in the level of cell-associated VDR (Fig. 3A) . Surprisingly, this increase was not associated with an increase in VDR mRNA levels (data not shown). Previous studies have shown that 1,25(OH) 2 D 3 , by increasing the half-life of the VDR protein, can increase VDR protein levels without increasing the VDR mRNA (21, 22) . Thus, a similar mechanism might be involved in the action of the drugs on VDR protein expression. These data thus exclude a decrease in VDR expression as a cause for the inhibitory effect of the drugs on 1,25(OH) 2 D 3 -stimulated up-regulation of CYP24 mRNA.
Effects of Antineoplastic Agents on the Activities of the ERK1/ERK2 and ERK5 MAP Kinases
We have previously showed that ERK1/ERK2 and ERK5 MAP kinases were required for 1,25(OH) 2 D 3 to stimulate the activity of the CYP24 gene promoter in VDR-transfected COS-1 cells (10). We therefore investigated whether the drugs prevented 1,25(OH) 2 D 3 from activating the MAP kinases. Daunorubicin hydrochloride and etoposide alone (data not shown) caused a modest increase in the activities of ERK1/ERK2 (Fig. 3B) and ERK5 (Fig. 3C) . However, neither daunorubicin (Fig. 3D ) nor etoposide (data not shown) prevented 1,25(OH) 2 D 3 from stimulating the activity of ERK5. Thus, it is highly unlikely that the drugs prevented 1,25(OH) 2 D 3 from stimulating the MAP kinases.
Effects of Antineoplastic Agents on the Activity of the CYP24 Promoter
The above data raised the possibility that the drugs could inhibit gene transcription downstream of the MAP kinases. To investigate this, COS-1 cells were transiently cotransfected with a construct that contained the firefly luciferase gene driven by the proximal À298 bp CYP24 promoter. This promoter region contains two well-characterized vitamin D response elements that mediate the genomic actions of 1,25(OH) 2 D 3 (23, 24) . Interestingly, daunorubicin hydrochloride per se stimulated the activity of the CYP24 promoter (Fig. 4A) , consistent with its effect on MAP kinases. The threshold of stimulation was f0.5 Amol/L and an EC 50 of f0.8 Amol/L. At lower doses (0.1 and 0.3 Amol/L), the drug also caused a synergistic increase in CYP24 promoter activity in the presence of 1,25(OH) 2 D 3 , but this effect was not observed at higher doses (Fig. 4A) . In the combined presence of 1,25(OH) 2 D 3 and daunorubicin hydrochloride, the EC 50 was f0.09 Amol/L. These data show that the drug can stimulate basal CYP24 promoter activity as well as cause a synergistic induction with 1,25(OH) 2 D 3 . Etoposide and vincristine sulfate per se also caused a small increase in CYP24 promoter activity (Fig. 4B) . In the presence of 1,25(OH) 2 D 3 , both drugs caused a synergistic increase in promoter activity. A synergistic interaction between the drugs and 1,25(OH) 2 D 3 on CYP24 promoter activity was also observed in HEK293T cells (data not shown).
We also tested a longer promoter construct that contained 1401 bp of the CYP24 promoter. The data show that the extra 1100 bp had no significant effect on the ability of either the cytotoxic agents or 1,25(OH) 2 D 3 per se to stimulate promoter activity in COS-1 cells (P > 0.05; Fig. 4C  and D) . However, the synergistic effect of 1,25(OH) 2 D 3 and daunorubicin hydrochloride was reduced with the À1401 bp promoter. Thus, whereas 1,25(OH) 2 D 3 and daunorubicin hydrochloride alone gave a 1.8-and 2.1-fold increase over controls, respectively, with the longer promoter, the combination produced a 5-fold increase. This compared with an approximate 13-fold increase with the À298 bp promoter construct. Thus, the coupling between the VDR and the CYP24 transcriptional machinery remained intact in the presence of the drugs.
Effect of Antineoplastic Agents on CYP24 mRNA Stability
The above observations suggest that the drugs could affect CYP24 mRNA at a posttranscriptional level. When HEK293T cells were incubated with 1,25(OH) 2 D 3 for 24 h, washed and actinomycin D added to stop transcription, the addition of daunorubicin hydrochloride, etoposide (Fig. 5A) , or vincristine sulfate (data not shown) enhanced the rate of decay of CYP24 mRNA. This effect was clearly evident within 1 to 2 h of drug treatment (Fig. 5A) . A destabilizing effect of the drugs on CYP24 mRNA was also observed in COS-1 cells (data not shown). These results imply that a drug-promoted instability of CYP24 mRNA nullified their promoter-enhancing action. Neither daunorubicin hydrochloride nor etoposide affected the stability of either the VDR or CYP27B1 mRNA within the same samples ( Fig. 5B and C) . All these data point to the possibility that the drugs promoted the degradation of CYP24 mRNA. Indeed, this was confirmed by our data. Concurrent investigations on the stability of the VDR and CYP27B1 mRNA species showed that the drugs did not affect the levels of the latter two mRNA species that have longer half-lives than the CYP24 mRNA. However, it is unlikely that mRNA half-life was a determinant of susceptibility to the drug-induced degradation. Studies on the stability of protein kinase Cd (25), Hox 2.1 (26), and vascular cell adhesion molecule (27) mRNA have shown a lack of correlation between mRNA half-life and the action of etoposide. Our observation that daunorubicin hydrochloride, etoposide, and vincristine sulfate promoted CYP24 mRNA degradation places these antineoplastic agents in the same category as parathyroid hormone (28) and the anti-HIV protease inhibitor, ritonavir (29) , which have been reported to promote CYP24 mRNA instability, thus identifying a novel action of the cytotoxic agents.
The enhanced rate of CYP24 mRNA degradation caused by the drugs most likely counteracted their positive effects on the CYP24 promoter. Thus, the overall reduction in 1,25(OH) 2 D 3 -mediated accumulation of CYP24 would be expected to preserve the levels of vitamin D metabolites and enhance or prolong their biological actions. Indeed, this concept is supported by a number of observations. Ritonavir, which also inhibits CYP24, increased the intracellular levels of 1,25(OH) 2 D 3 and potentiated the ability of 1,25(OH) 2 D 3 to induce growth arrest and differentiation of HL60 cells (29) . Similarly, genistein, ketoconazole, and liarozole, by inhibiting the activity of CYP24 or its expression, can amplify the antiproliferative effects of 1,25(OH) 2 D 3 in DU145 prostate cancer cells (30 -32) . These enhancing effects are consistent with our observation that the antineoplastic agents potentiated 1,25(OH) 2 D 3 -mediated activation of the CYP24 promoter. Furthermore, we have found the drugs to not only inhibit 1,25(OH) 2 D 3 -mediated increase in CYP24 mRNA in DU145 cells but the drug + 1,25(OH) 2 D 3 combination also caused an enhanced loss of viability of these cells. 8 These data suggest that our observations in cells of the kidney, the Figure 5 . Antineoplastic agents accelerated CYP24 mRNA degradation. HEK293T cells in serum-deficient medium were incubated with 1,25(OH) 2 D 3 (10 nmol/L) for 24 h, washed and the cells were then incubated with actinomycin D (5 Ag/mL; 0 h) and DMSO, etoposide (10 Amol/L), or daunorubicin hydrochloride (1 Amol/L) for up to 6 h. At the indicated times, triplicate wells from each group were removed, total RNA extracted, and CYP24 (A), VDR (B), and CYP27B1 (C) mRNA levels were determined by qRT-PCR. Significance of difference in CYP24 mRNA levels between vehicle and drug at the indicated time points: *, P < 0.05, **, P < 0.01 (Tukey-Kramer multiple comparisons test). Results are representative of two to four experiments. primary organ for bioactivation and inactivation of 1,25(OH) 2 D 3 , are also relevant to other cell types.
Our observations have important medical repercussions for anticancer therapy because the ability of the drugs to suppress 1,25(OH) 2 D 3 -mediated accumulation of CYP24 differed between them. In combination chemotherapy involving 1,25(OH) 2 D 3 and an antineoplastic agent, relatively high doses of 1,25(OH) 2 D 3 are generally required with the concomitant increase in risk of adverse side effects. Indeed, a major hurdle to achieving a favorable clinical response is the need for doses that are just below those that cause hypercalcemia and hypercalciuria (3). Our findings suggest that the choice of drugs is important in achieving the greatest suppression of CYP24 expression. As these anticancer drugs also increased VDR protein, it may be possible to reduce the dose of 1,25(OH) 2 D 3 to achieve a favorable clinical response because these effects would likely increase the sensitivity and responsiveness of cancer cells to 1,25(OH) 2 D 3 , in addition to prolonging its bioavailability as discussed above. Future studies could test this in a preclinical in vivo model. For example, it would be possible to treat mice with an antineoplastic agent for a few days in the presence or absence of 1,25(OH) 2 D 3 and examine the levels of CYP24 mRNA and VDR protein in the kidneys or another tissue, combined with the measurement of vitamin D metabolites. Given that different drugs exhibit different abilities at suppressing CYP24 mRNA accumulation, the ability of a range of antineoplastic agents to suppress CYP24 mRNA accumulation could be compared to identify those with the greatest suppressive ability.
In summary, this study has revealed a previously unknown mechanism of action of daunorubicin hydrochloride, etoposide, and vincristine sulfate and this new understanding is likely to contribute to approaches for improved anticancer therapy involving 1,25(OH) 2 D 3 and an antineoplastic agent.
